Agios will lead development and commercialization activities for AG-120 in the U.S., and Celgene retains the option to lead development and commercialization for AG-120 in the rest of the world. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein, and a targeted therapeutic candidate for the treatment of patients with cancers that have an IDH1 mutation.
The companies are also collaborating on the development of AG-221, an oral, selective, potent inhibitor of the mutated IDH2 protein, a targeted therapeutic candidate to treat patients with cancers that have an IDH2 mutation.
“The opportunity to develop and commercialize the IDH1 program in the U.S. market is a critical component of Agios’ long term strategy and vision to transform the lives of patients with cancer,” said David Schenkein, M.D., chief executive officer of Agios. “Celgene has been an exceptional partner for our cancer metabolism research efforts, and we are looking forward to the next phase of our collaboration with the global clinical development of the IDH2 and IDH1 programs.”